Mental Health DailyResearch. Evidence. Perspective.Published research on vraylar.
Vraylar (Cariprazine) is an atypical antipsychotic that is most frequently prescribed as a pharmacological intervention for schizophrenia and bipolar disorder. The medication functions predo…
Read articleVraylar (Cariprazine), is an atypical antipsychotic medication approved in 2015 by the FDA for the treatment of schizophrenia and bipolar disorder. Occasionally, Vraylar is also prescribed a…
Read articleVraylar (Cariprazine), also sold under the name Reagila [in European countries], is an atypical antipsychotic developed by the pharmaceutical company Allergan. In 2015, Vraylar received FDA …
Read articleVraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced…
Read article